NR3C1 and non-Hodgkin lymphoma: In addressing best practices for the clinical use of our inhibitor (EPZ-6438 or E7438) of the chromatin-modifying enzyme EZH2 together with currently used drugs for NHL patients, we have identified an unexpected interplay between GR signal transduction and EZH2-mediated chromatin modification, which we report here.